AIM ImmunoTech Provides Routine Update on Annual Filings
MWN-AI** Summary
AIM ImmunoTech Inc. (NYSE American: AIM) provided a routine update regarding its annual financial filings for the year ended December 31, 2025. The company's audited consolidated financial statements included an audit report from its independent accounting firm highlighting a "going concern" emphasis, as required by NYSE guidelines. Importantly, this report does not alter AIM's previous filings. The management expressed confidence in their ability to secure funding, bolstered by positive developments in clinical trials involving Ampligen, the company's lead drug for late-stage pancreatic cancer.
Recent results from a Phase 2 study (DURIPANC) demonstrated promising efficacy of Ampligen combined with AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer patients who exhibited stable disease following FOLFIRINOX treatment. AIM plans to provide further updates on this study in June 2026, showcasing ongoing commitment to its research endeavors.
AIM ImmunoTech focuses on developing Ampligen®, a well-researched immunomodulator showing potential benefits against multiple health conditions, including various cancers and immune disorders. However, AIM cautioned that many uncertainties, risks, and regulatory hurdles remain in the path to validating Ampligen's effectiveness through extensive human clinical trials. The company reiterated that preliminary data from animal studies cannot guarantee analogous human outcomes and that future trial results may differ significantly.
Investors are encouraged to review AIM’s latest risk factors and annual reports for a deeper understanding of the potential challenges ahead. The company is also navigating possible foreign operational risks regarding intellectual property rights. Overall, AIM ImmunoTech remains focused on advancing its clinical research while proactively communicating its financial outlook to stakeholders.
MWN-AI** Analysis
AIM ImmunoTech Inc. (NYSE American: AIM) has recently released an update regarding its annual filings, which included an audit report indicating a going concern. This highlights potential financial instability, implying that investors should exercise caution. The emphasis from auditors suggests that the company may face challenges in sustaining operations if funding is not secured, which raises concerns about long-term viability.
Despite these risks, management remains optimistic about its lead drug, Ampligen, and its potential effectiveness in treating late-stage pancreatic cancer. The promising results from the Phase 2 DURIPANC study, assessing Ampligen's efficacy alongside AstraZeneca's Imfinzi, could be a game-changer for the company if future updates maintain a positive trajectory. The next update expected in June 2026 will be crucial for investor sentiment.
Investors should consider both the risks and opportunities associated with AIM ImmunoTech. On one hand, the ongoing developments in clinical trials could lead to significant breakthroughs, potentially increasing the stock value. On the other hand, the existing going concern can lead to volatility and diminished investor confidence, particularly if the next update does not meet expectations.
In light of these factors, now may not be the ideal time to invest heavily in AIM ImmunoTech, especially for risk-averse investors. Rather, it would be wise to closely monitor upcoming announcements and the outcomes of clinical trials. This situation exemplifies the high stakes of biotech investments—where substantial potential rewards can be coupled with significant risks.
In conclusion, prospective investors should adopt a wait-and-see approach, assessing both the clinical trial outcomes and the company’s ability to secure necessary funding before making substantial financial commitments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
OCALA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today advised that its audited consolidated financial statements for the fiscal year ended December 31, 2025, contained an audit report from its independent registered public accounting firm with a going concern emphasis of matter. Release of this information is required by Section 610(b) of the NYSE American Company Guide, and does not represent any change or amendment to any of the Company’s filings for the fiscal year ended December 31, 2025.
AIM management is confident in its continued ability to raise funds based on ongoing, promising results in the development of its lead drug, Ampligen, for the treatment of late-stage pancreatic cancer. The Company recently reported positive progress in the Phase 2 clinical study evaluating Ampligen combined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care (the “DURIPANC” study). AIM expects to release the next DURIPANC update in June 2026.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.
Forward-Looking Statements
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in the press release speak only as of the date of the press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The Company is in various stages of seeking to determine whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and disclosures in the Company’s reports filed with the SEC on its website and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website and in its press releases. No assurance can be given that intention to seek Orphan Drug Designation will result in the granting of that status, nor that the possession of Orphan Drug Designations or any patents means that a drug will receive market approval. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.
Please review the “Risk Factors” section in the Company’s latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and the Registration Statement. Its filings are available at www.aimimmuno.com. The information found on the Company’s website is not incorporated by reference herein and is included for reference purposes only.
Investor Contact: JTC Team, LLCJenene Thomas908.824.0775AIM@jtcir.com
FAQ**
What specific steps is AIM ImmunoTech Inc. AIM taking to address the "going concern" emphasis noted in its independent audit report for the fiscal year ended December 32025?
How does AIM ImmunoTech Inc. AIM plan to leverage the promising results from the DURIPANC study to attract potential investors and secure additional funding?
Can you provide insights on any potential challenges AIM ImmunoTech Inc. AIM may face in obtaining regulatory approvals for Ampligen, especially considering the ongoing clinical trials?
What strategies is AIM ImmunoTech Inc. AIM implementing to mitigate the risks associated with its international operations, particularly in enforcing intellectual property rights abroad?
**MWN-AI FAQ is based on asking OpenAI questions about AIM ImmunoTech Inc. (NYSE: AIM).
NASDAQ: AIM
AIM Trading
58.02% G/L:
$0.405 Last:
123,467,102 Volume:
$0.2756 Open:
